Celator Pharma Completes Final Close with $32.5M Funding
May 06, 2013
Celator Pharmaceuticals, a clinical-stage developer of therapies to treat cancer, has raised $32.5 million in the final closing of its funding round led by Valence Life Sciences. The round totals $39.3 million, including $6.8 million from prior closings. With offices in Princeton, NJ and Vancouver, BC, Celator will use the capital to support the late stage clinical development of its lead investigational product, CPX-351 Liposome Injection. In conjunction with the financing, Valence Life Sciences managing director Scott Morenstein will join the company’s Board.